JP2017532959A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532959A5
JP2017532959A5 JP2017519013A JP2017519013A JP2017532959A5 JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5 JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5
Authority
JP
Japan
Prior art keywords
subject
gene
threshold
mdm2i
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017519013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/079389 external-priority patent/WO2016056673A1/en
Publication of JP2017532959A publication Critical patent/JP2017532959A/ja
Publication of JP2017532959A5 publication Critical patent/JP2017532959A5/ja
Withdrawn legal-status Critical Current

Links

JP2017519013A 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム Withdrawn JP2017532959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061992P 2014-10-09 2014-10-09
US62/061,992 2014-10-09
PCT/JP2015/079389 WO2016056673A1 (en) 2014-10-09 2015-10-09 Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017532959A JP2017532959A (ja) 2017-11-09
JP2017532959A5 true JP2017532959A5 (https=) 2018-11-22

Family

ID=54396934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519013A Withdrawn JP2017532959A (ja) 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム

Country Status (4)

Country Link
US (1) US20170283885A1 (https=)
EP (1) EP3204514A1 (https=)
JP (1) JP2017532959A (https=)
WO (1) WO2016056673A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
CN107974502B (zh) * 2016-10-19 2021-07-02 北京大学人民医院 一种用于同时检测nbpf10、tsfm、prb2及diaph1基因突变的试剂盒
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021228814A1 (en) * 2020-05-15 2021-11-18 ETH Zürich Mdm2 inhibitor response prediction method
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023009174A1 (en) * 2021-07-30 2023-02-02 Oregon Health & Science University Methods for predicting lymph node status, likelihood of metastasis, and/or overall prognosis in patients with melanoma
CN118398086B (zh) * 2024-04-19 2026-01-06 山东云海国创云计算装备产业创新中心有限公司 抗癌药物反应预测方法、装置、计算机设备及存储介质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2380892E (pt) * 2009-01-16 2014-06-09 Daiichi Sankyo Co Ltd Derivado de imidazotiazole compreendendo uma estrutura de anel prolina
AU2012226890B2 (en) * 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
US20120328692A1 (en) * 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
US9371568B2 (en) * 2012-07-31 2016-06-21 Novartis Ag Markers associated with human double minute 2 inhibitors
WO2014065760A1 (en) * 2012-10-25 2014-05-01 Agency For Science, Technology And Research Methods for determining resistance against molecules targeting proteins
BR112015031542A2 (pt) * 2013-07-03 2017-07-25 Hoffmann La Roche métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores

Similar Documents

Publication Publication Date Title
JP2017532959A5 (https=)
Westphal et al. Circulating biomarkers for gliomas
Fry et al. Activation of inflammation/NF-κB signaling in infants born to arsenic-exposed mothers
JP2017508442A5 (https=)
JP2021501318A5 (https=)
JP2010518811A5 (https=)
Sabo-Attwood et al. Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis
Anaka et al. Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
Liu et al. A single-cell transcriptional landscape of immune cells shows disease-specific changes of T cell and macrophage populations in human achalasia
Zhang et al. Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma
Teferi et al. The vaccinia virus K7 protein promotes histone methylation associated with heterochromatin formation
Cruz‐Granados et al. Multiomic‐based immune response profiling in migraine, vestibular migraine and Meniere's disease
Yu et al. Genome-wide analysis of genetic variations assisted by Ingenuity Pathway Analysis to comprehensively investigate potential genetic targets associated with the progression of hepatocellular carcinoma
Qi et al. A four-mRNA model to improve the prediction of breast cancer prognosis
CN113736879A (zh) 用于小细胞肺癌患者预后的系统及其应用
Li et al. Significance of pyroptosis-related gene in the diagnosis and classification of rheumatoid arthritis
JP2018538247A5 (https=)
Yang et al. Single‐cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers
Lu et al. Dysregulation of TFDP1 and of the cell cycle pathway in high-grade glioblastoma multiforme: a bioinformatic analysis
Cho et al. Involvement of DDX6 gene in radio-and chemoresistance in glioblastoma
Zou et al. Identification of key modules and prognostic markers in adrenocortical carcinoma by weighted gene co‑expression network analysis
Peña et al. Multiplexed digital mRNA profiling of the inflammatory response in the West Nile Swiss Webster mouse model
Yang et al. Construction of cuproptosis‑associated prognostic signature in colon adenocarcinoma based on bioinformatics and RT‑qPCR analysis
CN105653896A (zh) 高通量测序突变检测结果验证方法
WO2021249355A1 (zh) 用于选择化疗响应患者组的生物标志物和方法及其用途